Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $0
- PE ratio
- —
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- —
Trading
- Volume
- 125
- Avg volume
- 7,920
- Day's range
- $0.00 – $0.00
- Shares out
- —
- Stochastic %K
- 0%
- Beta
- —
- Analysts
- Strong Buy
- Price target
- —
Company profile
ObsEva SA, a biopharmaceutical company, focuses on the development of novel therapies to improve women's reproductive health. It develops Nolasiban, an oral oxytocin receptor agonist for improving clinical pregnancy and live birth rates in women undergoing in-vitro fertilization. The company was founded in 2012 and is headquartered in Geneva, Switzerland.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 41 22 552 38 40
- Website
- https://www.obseva.com
- Address
- Chemin des Aulx, 12, Plan-les-Ouates, Geneva, Switzerland
Latest news
No headlines yet.
